The international cannabis firm Curaleaf Holdings Inc. has published a point-by-point fact sheet aimed at rebutting statements from Aurora Cannabis Inc. after Curaleaf unveiled a proposal to acquire the Aurora-based company.
The document, issued by Curaleaf on Sept. 8 from Stamford, Conn., frames the debate for shareholders around contrasting visions for the future and differing records on value creation. Curaleaf’s filing stresses what it says are misleading statements from Aurora and urges shareholders to weigh tangible results over promises.
Curaleaf’s key claims and numbers
In its materials, Curaleaf emphasises a number of financial and operational figures to make its case:
- 45% — the premium Curaleaf says its offer represents, which it describes as among the higher premiums in Canadian mergers and acquisitions over the past decade.
- 110% — the premium Curaleaf calculates when excluding cash on Aurora’s balance sheet.
- C$5 billion — impairments Aurora recorded, according to Curaleaf, during years of attempted restructuring.
- C$130 million — business transformation costs Curaleaf cites for Aurora.
- More than C$480 million — cumulative negative operating cash flow since fiscal 2021, per Curaleaf’s fact sheet.
- 97% — the percentage decline in Aurora’s share price cited by Curaleaf under the company's current chief executive, Miguel Martin.
"Curaleaf believes shareholders deserve the facts."
Curaleaf also questions Aurora’s choice to continue issuing shares through an at-the-market (ATM) program at prices Curaleaf regards as ‘‘materially below’’ the value implied by its offer. The fact sheet asks why Aurora management would dilute shareholders at those prices if it truly believed the company was worth materially more.
Local stakes for Aurora
Although Curaleaf is based in the United States, the target of the proposal is a company with deep ties to this town. Any change of control could carry implications for employees, local service providers and municipal tax interests tied to Aurora Cannabis and its operations.
Residents here will be watching how the shareholder debate unfolds: whether Aurora’s board and management can make the case for a standalone recovery plan that addresses the impairments and cash-flow shortfalls Curaleaf highlights, or whether shareholders will accept the takeover premium being offered.
What the numbers mean — a quick comparison
| Item | Curaleaf figure |
|---|---|
| Acquisition premium (stated) | 45% |
| Premium excl. Aurora cash | 110% |
| Impairments recorded | C$5 billion |
| Business transformation costs | C$130 million |
| Negative operating cash flow since FY21 | > C$480 million |
Curaleaf’s emphasis on these figures is designed to contrast its track record and valuation argument with Aurora’s independent plan. The broader question for local stakeholders is whether Aurora’s management can point to concrete progress that reverses the trends Curaleaf cites.
Next steps and potential outcomes
The dispute is likely to play out in investor communications, board deliberations and potentially a shareholder vote if an offer proceeds. Curaleaf’s public fact sheet seeks to shape the narrative ahead of those decisions by urging investors to focus on measurable results.
For Aurora residents, the immediate consequence will be heightened scrutiny of the company’s public statements and financial disclosures. For employees and local suppliers, the uncertainty could linger until the corporate direction is clarified. Municipal officials typically monitor such developments closely because they can affect local employment and economic activity, even if they do not directly manage corporate governance.
Curaleaf’s materials and Aurora Cannabis’s responses will be important reading for anyone with a stake in the company’s future here in town. As the debate continues, shareholders will be asked to weigh the premiums Curaleaf is offering against the promise of a renewed, independent Aurora — with the town’s economic ties to the company hanging in the balance.
